Jazz Pharmaceuticals

Nasdaq: JAZZ ↗ $224.66 USD ~$7B MCAP

#Neuroscience (Narcolepsy, Epilepsy)#Small Cell Lung Cancer (SCLC)#Oncology #Rare Pediatric Epilepsy #Specialty Therapeutics

Jazz Pharmaceuticals is a global biopharmaceutical company focused on neuroscience and oncology, with a commercial portfolio that includes Xywav (low-sodium oxybate), Epidiolex (cannabidiol), and Zepzelca (lurbinectedin). The company markets Zepzelca in the U.S. under license from PharmaMar and is facing renewed questions about the drug's accelerated approval in small cell lung cancer after a confirmatory Phase 3 trial failed to meet its primary endpoint.

Company Info

Sector: Pharmaceutical / Specialty Therapeutics (Neuroscience & Oncology)

Headquarters: Dublin, Ireland (with U.S. operations in Palo Alto, California and Philadelphia, Pennsylvania)

Founded: 2003

Website: www.jazzpharma.com/

Upcoming Milestones & Key Dates

H2 2026

Regulatory

FDA Oncologic Drugs Advisory Committee on Zepzelca confirmatory data and accelerated approval status

Q3 2026

Earnings

Q2 2026 earnings and Zepzelca commercial update

Clinical Development Pipeline

Zepzelca (lurbinectedin)

Target: Marine-derived alkylating agent binding DNA minor groove

Relapsed small cell lung cancer (SCLC) — confirmatory Phase 3 failed June 2026

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Xywav (calcium, magnesium, potassium, and sodium oxybates)

Target: GABA-B receptor modulation (low-sodium oxybate formulation)

Cataplexy and excessive daytime sleepiness in narcolepsy; idiopathic hypersomnia

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Epidiolex/Epidyolex (cannabidiol)

Target: Plant-derived cannabinoid (non-psychoactive)

Seizures associated with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Jazz turns to AbCellera for T cell engagers against GI cancers in up to $4.1B deal ↗

Jazz Pharmaceuticals signs a deal worth up to $4.1B with AbCellera to develop T cell engagers against gastrointestinal cancers, expanding Jazz's oncology pipeline beyond its existing CNS focus.

Clinical Regulatory • Jun 12, 2026 • Fierce Pharma

Zepzelca Saga Takes Another Turn With Ph. 3 Lung Cancer Flop ↗

Jazz Pharmaceuticals and partner PharmaMar's Zepzelca (lurbinectedin) has failed a confirmatory Phase 3 study in small cell lung cancer, raising fresh questions about the drug's accelerated approval and Jazz's oncology strategy.

Leadership Team

To be confirmed

Chief Executive Officer

To be confirmed

Chief Medical Officer

To be confirmed

Chief Financial Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →